

# Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment

14 March 2012

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

This potential new [drug target](#) belongs to a class of receptors called the nicotinic acetylcholine receptors (nAChRs). One subtype of nAChRs, called alpha4beta2 is a well-known target for nicotine's [addictive effects](#) and the therapeutic effect of the [smoking cessation](#) drug varenicline. SRI researchers are now studying another, lesser-known subtype, called alpha3beta4 nAChR, which has recently shown to play a role in the addictive properties of cocaine, morphine, and nicotine.

Using AT-1001, a highly selective alpha3beta4 compound developed by Astraea Therapeutics, SRI researchers found that addiction processes could be disrupted. In preliminary studies, AT-1001 also reduced nicotine withdrawal symptoms such as anxiety.

Because [addictive drugs](#) act on the brain's "reward circuit," many people compulsively take them despite their harmful consequences. Feelings of pleasure are caused by the release of [brain chemicals](#), or neurotransmitters, and their increased activity in the [brain reward](#) circuit. The key neurotransmitter in the reward circuit is dopamine, which produces changes in addictive behavior. Researchers speculate that disruption of the alpha3beta4 nAChR system using highly selective drugs such as AT-1001 may interrupt this reward circuitry.

"Currently, there are no therapeutics approved to treat addiction to stimulants such as cocaine, so it is intriguing to find a promising drug receptor target and to see that AT-1001 can indeed affect

phenomena that are thought to be deeply tied to the addictive nature of cocaine and other drugs of abuse," said Taline Khroyan, Ph.D., Senior Behavioral Pharmacologist in SRI's Center for Health Sciences.

Findings from these collaborative studies were recently presented at the Society for Neuroscience Annual Meeting in a study titled "AT-1001, a Highly Selective alpha3beta4 nicotinic Receptor Antagonist is Effective in Blocking Place Preference, Behavioral Sensitization, and Withdrawal Effects of Various Drugs of Abuse." The presentation was highlighted by the Society for describing the innovative approach taken by the research team.

Provided by SRI International

APA citation: Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment (2012, March 14) retrieved 28 April 2021 from <https://medicalxpress.com/news/2012-03-collaborative-preclinical-efficacy-drug-addiction.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*